An open-label extension of two pivotal clinical trials has given ophthalmologists critical, real-world evidence of the effectiveness of adalimumab as a treatment of noninfectious intermediate uveitis.
Modern Medicine Cases
An intravitreal injection device can provide repeatable results and added comfort for the patient, removing the need for a drape and speculum.
Two patients with macular degeneration regained reading vision after receiving stem cells implanted with a new technique, according to researchers.
Preliminary research has shown that ataluren is effective in overriding the nonsense mutation in choroideremia patients, however, further research is needed.
A study has revealed that a budgetary saving per treated patient with the fluocinolone acetonide implant (Iluvien) versus ranibizumab (Lucentis) could lead to a significant cost-saving to NHS England.
A low dose of ranibizumab (Lucentis, Genentech/Roche) works well as a treatment for retinopathy of prematurity (ROP), researchers say.
Real-world data on a fluocinolone acetonide intravitreal implant show sustained benefits of switching to the treatment in pseudophakic eyes that are insufficiently responsive to other therapies.
OCT has many benefits, yet falls short of reliably diagnosing and managing retinopathies and glaucoma. ERG remains the stalwart method for this application and this article highlights how technological advancements have enabled its introduction to the clinic.
A dark adaptometer (AdaptDx; MacuLogix Inc) can aid in the diagnosis of early-stage, or subclinical, age-related macular degeneration before visual loss occurs and even before structural changes are observed, and adds to the information obtained from retina cameras and OCT imaging.